Clorox (CLX) Is Consistent, Says Jim Cramer

Core Viewpoint - The Clorox Company (NYSE:CLX) has shown mixed performance, with a 19% decline over the past year but an 18% increase year-to-date, indicating potential recovery and investment interest [1]. Group 1: Stock Performance - Clorox shares are down by 19% over the past year but have increased by 18% year-to-date [1]. - Wells Fargo raised its price target for Clorox from $108 to $115 while maintaining an Equal Weight rating [1]. - JPMorgan increased Clorox's price target from $114 to $117, keeping a Neutral rating [1]. Group 2: Financial Performance - In its February earnings report, Clorox reported earnings per share of $1.39 and revenue of $1.67 billion [1]. - The earnings missed analyst estimates of $1.43, while revenue exceeded estimates of $1.64 billion [1]. Group 3: Strategic Moves - Clorox's acquisition of the firm responsible for manufacturing Purell hand sanitizer is expected to drive sales growth in the low double-digit percentages [1].